Clicky

BioCryst Pharmaceuticals, Inc.(BCRX) News

Date Title
Apr 10 How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry
Mar 1 Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?
Feb 27 BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Feb 26 Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher
Feb 26 Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know
Feb 24 BioCryst: Q4 Earnings Snapshot
Feb 24 BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
Feb 24 BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years
Feb 17 BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Feb 12 BioCryst Launches ORLADEYO® (berotralstat) in Portugal
Feb 10 Exploring Three High Growth Tech Stocks In The United States
Feb 10 BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
Feb 10 BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
Jan 14 BioCryst price target raised to $12 from $10 at Evercore ISI
Jan 10 Exploring High Growth Tech Stocks In January 2025
Jan 10 BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
Jan 7 BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
Oct 11 Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler?
Oct 10 BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
Oct 9 BioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2